Geographical variation in the response of lupus nephritis to mycophenolate mofetil induction therapy

Clinical Nephrology

Volumn 75, Issue 3, 2011, Pages 233-241

  Mohan, S ^a   Radhakrishnan, J ^a  

^a Columbia University College of Physicians and Surgeons ^*  (United States)

Author keywords

Cyclophosphamide; Induction therapy; Lupus nephritis; Meta analysis; Mycophenolate mofetil

Indexed keywords

CYCLOPHOSPHAMIDE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER;

ARTICLE; ASIA; CLINICAL TRIAL (TOPIC); GEOGRAPHY; HUMAN; LUPUS ERYTHEMATOSUS NEPHRITIS; MAJOR CLINICAL STUDY; META ANALYSIS; MULTICENTER STUDY; RANDOMIZED CONTROLLED TRIAL (TOPIC); REMISSION;

ASIAN CONTINENTAL ANCESTRY GROUP; CONTINENTAL POPULATION GROUPS; CYCLOPHOSPHAMIDE; HUMANS; IMMUNOSUPPRESSIVE AGENTS; LUPUS NEPHRITIS; MYCOPHENOLIC ACID; REMISSION INDUCTION; RISK ASSESSMENT; RISK FACTORS; TREATMENT OUTCOME;

EID: 79951858797     PISSN: 03010430     EISSN: None     Source Type: Journal    
DOI: 10.5414/CNP75233     Document Type: Article

References (26)

1. Cameron JS. Lupus Nephritis. J Am Soc Nephrol. 1999; 10: 413-424.
2. Austin H, Kilippel J, Balow J, le Riche N, Steinberg A, Plotz P, Decker J. Therapy of lupus nephritis. Controlled trial of prednisone and cytotoxic drugs. N Engl J Med. 1986; 314: 614-619. (Pubitemid 16132725)
3. Ginzler EM, Dooley MA, Aranow C, Kim MY, Buyon J, Merrill JT, Petri M, Gilkeson GS, Wallace DJ, Weisman MH, Appel GB. Mycophenolate mofetil or intravenous cyclophosphamide for lupus nephritis. N Engl J Med. 2005; 353: 2219-2228. (Pubitemid 41697285)
4. Chan TM, Li FK, Tang CS, Wong R, Fang G, Ji Y, Lau C, Wong A, Tong M, Chan K, Lai K and group THKGN. Efficacy of myophenolate mofetil in patients with diffuse proliferative lupus nephritis. N Engl J Med. 2000; 343: 1156-1162.
5. Walsh M, James M, Jayne D, Tonelli M, Manns BJ, Hemmelgarn BR. Mycophenolate mofetil for induction therapy of lupus nephritis: a systematic review and meta-analysis. Clin J Am Soc Nephrol. 2007; 2: 968-975.
6. Zhu B, Chen N, Lin Y, Ren H, Zhang W, Wang W, Pan X, Yu H. Mycophenolate mofetil in induction and maintenance therapy of severe lupus nephritis: a meta-analysis of randomized controlled trials. Nephrol Dial Transplant. 2007; 22: 1933-1942. (Pubitemid 47244763)
7. Moore RA, Derry S. Systematic review and meta-analysis of randomised trials and cohort studies of mycophenolate mofetil in lupus nephritis. Arthritis Res Ther. 2006; 8: 182.
8. Appel GB, Contreras G, Dooley MA, Ginzler EM, Isenberg D, Jayne D, Li L-S, Mysler E, Sanchez- Guerrero J, Solomons N, Wofsy D, the Aspreva Lupus Management Study G. Mycophenolate mofetil versus cyclophosphamide for induction treatment of lupus nephritis. J Am Soc Nephrol. 2009; 20: 1103-1112.
9. Choi KH, Moon S, Han S, Lee J, Kim D, Kim B, Kang S, Han D, Lee H. The comparison study between mycophenolate mofetil and cyclophosphamide for treatment of proliferative lupus nephritis. J Am Soc Nephrol. 2007; 18: 566.
10. Wang J, Hu W, Xie H, Zhang H, Chen H, Zeng C, Liu Z, Li L. Induction therapies for class IV lupus nephritis with non-inflammatory necrotizing vasculopathy: mycophenolate mofetil or intravenous cyclophosphamide. Lupus. 2007; 16: 707-712. (Pubitemid 47517865)
11. Tang Z, Yang G, Yu C, Yu Y, Wang J, Hu W, Zeng C, Chen H, Liu Z, Li L. Effects of mycophenolate mofetil for patients with crescentic lupus nephritis. Nephrology (Carlton). 2008; 13: 702-707.
12. Traitanon O, Avihingsanon Y, Kittikovit V, Townamchai N, Kanjanabuch T, Praditpornsilpa K, Wongchinasri J, Tungsanga K, Eiam-Ong S. Efficacy of enteric-coated mycophenolate sodium in patients with resistant-type lupus nephritis: a prospective study. Lupus. 2008; 17: 744-751.
13. Barr RG, Seliger S, Appel GB, Zuniga R, D'Agati V, Salmon J, Radhakrishnan J. Prognosis in proliferative lupus nephritis: the role of socio-economic status and race/ethnicity. Nephrol Dial Transplant. 2003; 18: 2039-2046. (Pubitemid 37220309)
14. Korbet SM, Schwartz MM, Evans J, Lewis EJ. Severe lupus nephritis: racial differences in presentation and outcome. J Am Soc Nephrol. 2007; 18: 244-254. (Pubitemid 46070148)
15. Chan TM, Tse KC, Tang CS, Mok MY, Li FK. Long-term study of mycophenolate mofetil as continuous induction and maintenance treatment for diffuse proliferative lupus nephritis. J Am Soc Nephrol. 2005; 16: 1076-1084. (Pubitemid 41710318)
16. Bradburn M, Deeks J, Altman D. Metan-a command for meta-analysis in Stata. In: J.A. Sterne (eds). Meta-analysis in Stata: an updated collection from the Stata journal. College Station: Stata Press: 2000. 3-29.
17. Deeks J, Altman D, Bradburn M. Statistical methods for examining heterogeneity and combining results from several studies in meta-analysis. In: M. Egger, G. Smith and D. Altman (eds). Systematic reviews in health care: Meta-analysis in context. London: BMJ Books: 2001. 285-312.
18. Steichen T. Tests for publication bias in meta-analysis. In: J. A. Sterne (eds). Meta-analysis in Stata: an updated collection from the Stata journal. College Station: Stata press: 2009. 151-162.
19. Flores-Suarez LF. Remission of severe relapsing or persistent lupus nephritis using mycophenolate mofetil. Arch Med Res. 2006; 37: 68-73. (Pubitemid 41727893)
20. Ong LM, Hooi LS, Lim TO, Goh BL, Ahmad G, Ghazalli R, Teo SM, Wong HS, Tan SY, Shaariah W, Tan CC, Morad Z. Randomized controlled trial of pulse intravenous cyclophosphamide versus mycophenolate mofetil in the induction therapy of proliferative lupus nephritis.Nephrology (Carlton). 2005; 10: 504-510.
21. Duncan N, Cairns T, Griffith M, McLean A, Palmer A, Taube D. Mycophenolate mofetil as treatment for the nephrotic syndrome caused by lupus nephritis. J Am Soc Nephrol. 2003; 14: 379.
22. Hu W, Liu Z, Chen H, Tang Z, Wang Q, Shen K, Li L. Mycophenolate mofetil vs cyclophosphamide therapy for patients with diffuse proliferative lupus nephritis. Chin Med J (Engl). 2002; 115: 705-709. (Pubitemid 34594285)
23. Chen Y, Korbet SM, Katz R, Schwartz MM, Lewis EJ. Value of a complete or partial remission in severe lupus nephritis. Clin J Am Soc Nephrol. 2008; 3: 46-53.
24. Mak A, Cheak AAC, Tan JYS, Su HC, Ho RCM, Lau CS. Mycophenolate mofetil is as efficacious as, but safer than, cyclophosphamide in the treatment of proliferative lupus nephritis: a meta-analysis and meta-regression. Rheumatology. 2009; 48: 944-952.
25. Isenberg D, Appel GB, Contreras G, Dooley MA, Ginzler EM, Jayne D, Sanchez-Guerrero J, Wofsy D, Yu X, Solomons N. Influence of race/ethnicity on response to lupus nephritis treatment: the ALMS study. Rheumatology. 2010; 49: 128-140.
26. Gordon C, Jayne D, Pusey C, Adu D, Amoura Z, Aringer M, Ballerin J, Cervera R, Calvo-Alen J, Chizzolini C, Dayer J, Doria A, Ferrario F, Floege J, Guillevin L, Haubitz M, Hiepe F, Houssiau F, Lesavre P, Lightstone L, Meroni P, Meyer O, Moulin B, Reilly K, Praga M, Schulze-Koops H, Sinico R, Smith K, Tincani A, Vasconcelos C, Hughes G. European Consensus statement on the terminology used in the management of lupus glomerulonephritis. Lupus. 2009; 18: 257-263.